Posted by Michael Wonder on 24 Mar 2021
Chugai obtains approval for Polivy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma
23 March 2021 - Polivy is approved as a first in class anti-CD79b antibody-drug conjugate based on data including the Japanese Phase 2 study and the overseas Phase 1b/2 study for relapsed or refractory diffuse large B-cell lymphoma.
Chugai Pharmaceutical announced today that it obtained approval from the Ministry of Health, Labour and Welfare for the anticancer agent/antimicrotubule binding anti-CD79b monoclonal antibody Polivy intravenous infusion 30 mg and 140 mg for use in combination with bendamustine and rituximab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
